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Abstract 
Background: Deep immune receptor sequencing, RepSeq, provides unprecedented 
opportunities for identifying and studying condition-associated T-cell clonotypes, 
represented by T-cell receptor (TCR) CDR3 sequences. However, due to the immense 
diversity of the immune repertoire, identification of condition relevant TCR CDR3s from 
total repertoires has mostly been limited to either “public” CDR3 sequences or to com-
parisons of CDR3 frequencies observed in a single individual. A methodology for the 
identification of condition-associated TCR CDR3s by direct population level comparison 
of RepSeq samples is currently lacking.
Results: We present a method for direct population level comparison of RepSeq 
samples using immune repertoire sub-units (or sub-repertoires) that are shared across 
individuals. The method first performs unsupervised clustering of CDR3s within each 
sample. It then finds matching clusters across samples, called immune sub-repertoires, 
and performs statistical differential abundance testing at the level of the identi-
fied sub-repertoires. It finally ranks CDR3s in differentially abundant sub-repertoires 
for relevance to the condition. We applied the method on total TCR CDR3β RepSeq 
datasets of celiac disease patients, as well as on public datasets of yellow fever vaccina-
tion. The method successfully identified celiac disease associated CDR3β sequences, as 
evidenced by considerable agreement of TRBV-gene and positional amino acid usage 
patterns in the detected CDR3β sequences with previously known CDR3βs specific to 
gluten in celiac disease. It also successfully recovered significantly high numbers of pre-
viously known CDR3β sequences relevant to each condition than would be expected 
by chance.
Conclusion: We conclude that immune sub-repertoires of similar immuno-genomic 
features shared across unrelated individuals can serve as viable units of immune reper-
toire comparison, serving as proxy for identification of condition-associated CDR3s.
Keywords: TCR differential abudance analysis, Celiac disease associated TCR 
clonotypes, Immune repertoire analysis, TCR repertoire analysis, Immuno-informatics, 
Antigen-specific TCR identification, Computational antigen-specificity identification, 
TCR clustering
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Background
Targeted high-throughput sequencing of T-cell receptors, RepSeq, has enabled in-depth 
profiling of immune repertoires [1]. One critical application of RepSeq technology is the 
identification of condition-associated T-cell clones based on observed changes in T-cell 
clone frequencies. This allows the tracking of immune cells that have expanded or con-
tracted following antigen exposure or treatment. Such analysis, however, is complicated 
by the fact that T-cell receptor (TCR) sequences are highly diverse, with estimated tens 
of millions of unique TCR expressing T-cell clones largely unique to individuals [2, 3], 
making direct comparison of T-cell clone abundances across multiple sample groups 
challenging.
A frequently used approach to the identification of condition-specific clonotypes 
across sample groups is the investigation of the so called public clonotypes (represented 
typically by unique TCR CDR3 sequences), which are commonly observed across many 
individuals [4–11]. However, such shared clonotypes make up a small portion of the 
total immune response in each individual. For instance, others and we have found that 
only around 10% of the response to gluten in celiac disease (CD) patients involves pub-
lic CDR3 sequences [9, 12]. Thus, more should be learned about the adaptive immune 
response by also studying the private response. There are currently few methods that 
allow detection of both private and public disease-relevant clonotypes. DeWitt et  al. 
reported a method that compares frequencies of clonotypes in repertoires sampled 
from the same individual to identify differentially abundant clonotypes, thus identify-
ing disease-relevant clonotypes within each individual [13]. An improved variant of 
the method in DeWitt et al. accounting for time-dependent variation was also reported 
[14]. A recent method called ALICE [15] allows detection of relevant clonotypes from 
single repertoires by comparing observed number of TCR neighbors against expected 
number of neighbors estimated from data generated using a statistical TCR recombina-
tion model. Pogorelyy et al. also reported a Bayesian statistical method for comparing 
and detecting expanded/relevant clonotypes between repertoires of same individual at 
different time points [16]. These methods allow the identification of interesting clones, 
which are also private to individuals, but do not allow the direct investigation of dif-
ferentially abundant clonotypes at the population level although ad hoc combining of 
results from multiple samples is still possible. Moreover, except ALICE, the methods 
require acquisition of multiple samples from each individual. Thus, there is currently a 
need for methods that perform direct population level comparison of clonal differential 
abundance for the identification of condition-specific T-cell clonotypes in longitudinal 
or case–control RepSeq datasets.
We recently showed that over-represented amino acid motifs in CD-associated TCR 
CDR3β sequences, originally identified from tetramer binding antigen-reactive T-cells 
[17, 18], were also detectable from the unsorted total peripheral blood immune reper-
toires of celiac disease patients despite the immense repertoire diversity [9]. This obser-
vation and closer inspection of the CD-associated TCR CDR3β sequences, strongly 
suggested that CDR3β sequences associated to CD exhibit sequence-level similarities 
that can be used to group them into clusters, reflecting similar immuno-genomic fea-
tures involved in the immune reaction that are possibly shared by patients. Such high 
sequence similarity had been observed in B-cell receptors (BCRs) associated to chronic 
Page 3 of 21Yohannes et al. BMC Bioinformatics          (2021) 22:159  
lymphocytic leukemia (referred to as BCR stereotypy), with potential clinical relevance 
[19, 20]. More recently, Dash et al. and Glanville et al. have shown that antigen-specific 
TCR sequences collected from different patients could be clustered into antigen specific-
ity groups that share sequence similarity [21, 22]. Overall, recent RepSeq studies have 
reported sequence similarity in CDR3 sequences associated with conditions, a charac-
teristic of the immune response that could be harnessed for the identification of con-
dition relevant CDR3 sequences from total unsorted repertoires by comparing sample 
groups.
In this work, we propose differential abundance analysis at the level of shared clus-
ters of T-cell receptor CDR3β sequences, called sub-repertoires, to enable identification 
of disease relevant clusters of CDR3β sequences by comparing RepSeq experimen-
tal groups. We first applied within-sample CDR3β clustering to reduce the diversity 
of immune repertoires into manageable and comparable units of analysis. We showed 
that these clusters of receptors, made up of clonotypes with highly similar frequen-
cies of nucleotide or amino acid subsequences (k-mers), form biologically meaningful 
units of analysis since they are commonly present in repertoires of unrelated individu-
als. We then performed statistical differential abundance analysis at the level of these 
sub-repertoires for the identification of condition-specific CDR3β clonotypes. We also 
showed that this methodology allows successful detection of condition-associated CDR3 
sequences, both private and public, from immune repertoire datasets of unrelated HLA-
matched celiac disease patients, and yellow fever virus vaccination volunteers, by com-
paring groups of samples at the population level.
Results
We hypothesized that clustering of CDR3s in the global repertoire not only reduces the 
enormous diversity of the immune repertoires into manageable units, but also has the 
potential for allowing indirect detection of condition associated CDR3s by first com-
paring the abundance of CDR3 clusters between sample groups (Fig. 1). To investigate 
the validity of such an approach, we first evaluated if a cluster of CDR3β sequences in 
one sample could be similar, in terms of subsequence composition, to another cluster in 
another sample. Importantly, the cluster must be closer to its match in another sample 
than it is to other clusters of CDR3βs in its home sample, ideally incorporating informa-
tion not just from the germline-encoded variable (V), diversity (D) and/or joining (J) 
regions but also from the non-templated nucleotides in the N1 and N2 regions, signi-
fying conserved immuno-genomic as well as antigen induced TCR selection features 
across samples.
We observed that such clusters of CDR3βs, with closely similar subsequence composi-
tion, exist across samples in unrelated individuals. For example, for the two CD PBMC 
repertoire samples CD005 and CD006 (unrelated celiac disease patients), we first sub-
sampled 5000 CDR3βs each from their total unique nucleotide CDR3β sequences, and 
performed unsupervised clustering of the CDR3βs within each sample. The centroids of 
all clusters from both samples were then pooled, and clustered again to identify match-
ing CDR3β cluster centroids (steps 1 and 2 on Fig. 1). Out of the 32 identified centroid 
clusters i.e., sub-repertoires, 30 (~ 94%) had centroids representing CDR3β clusters 
from both samples (Fig. 2a). The same analysis on all 8 samples of CD PBMC dataset 
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showed similar result, with all sub-repertoires having representative centroids from 
multiple samples (Additional file 1: Fig. 2Sa). As this could be expected if clusters are 
largely defined by germline-encoded V, D and J genes, we performed a number of analy-
ses to assess the extent to which such nucleotide 4-mer defined clusters are influenced 
by germline sequences. We first compared V-gene, VJ-gene, VDJ-gene and J-gene usage 
profiles between matching clusters in sub-repertoires. In both the two sample and all 8 
CDR3 clustering (within each sample)
CDR3 sequence … AGAT AGCA AGCC …
TGTGCCAGCAGTCCTAGGTCGTACAATGAGCA 0 2 0
TGCAGTGCTAGTATACTAGCGGGAGGGCCCACAGATACGCA 1 0 0
TGTGCCAGCAGCCAAGATTTTTTAAGCATTAATGAAAAACT 1 2 1
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T A CC ATTC ACGAG G A TTC
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Cluster centroids … AGAT AGCA AGCC …
C1 0 2 0
C2 1 0 0
C3 1 1.5 1
Sample 1 Sample 2 Sample 3 ...
Cluster matching (across samples)
Sample 1 Sample 2 Sample 3 …
SubRep 1 C2 C5 C3
SubRep 2 C2 C4 C2
SubRep 3 C1 C3 C6
SubRep 4 C4 C1 C4
SubRep 5 C5 C2 C5
Differen al Abundance (DA) tes ng
** DA Sub-repertoire
Sample 1 Sample 2 Sample 3 … LogFC
SubRep 1 C1 C5 C3 -0.49
SubRep 2 C2 C4 C2 0.30
SubRep 3 C3 C3 C1 -0.20
SubRep 4 C4 C1 C4 0.01
SubRep 5 C5 C2 C5 2.00 ** DA Sub-repertoire
Filtering candidate DA CDR3 sequences
CDR3 Sequence DA Sub-Repertoire Rank P-val
1 SubRep 2 0.01
2 SubRep 2 0.07
3 SubRep 2 0.10
4 SubRep 5 0.001




Fig. 1 Schematic of the clustering-based differential abundance detection methodology for CDR3 repertoire 
HTS datasets
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sample analyses, germline genes do not completely explain the subsequence composition 
similarity in matching clusters, with around 50% for V-gene and J-gene, and up to 80% 
for VJ- and VDJ- genes, of the sub-repertoires containing matching clusters with signifi-
cantly different gene usage profiles (Fig. 2b and Additional file 1: Fig. 2Sb and c). We then 
looked at the diversity of nucleotide 4-mers that start at each position of CDR3s (from 
a single sample) starting from the conserved cysteine to the end of the CDR3s. This was 
done for CDR3s with the most prevalent CDR3 length of 42 (Additional file 1: Fig. 2Sd). 
As we expected, we generally observed low diversity/variation of possible 4-mers in 
positions that only have germline genes and the highest 4-mer diversity in positions 
that have N1 and N2 regions (Fig. 2c), suggesting k-mer frequency estimates would be 
most different among k-mers that appear in these high entropy regions. We thus evalu-
ated the regions of CDR3s from where 4-mers with the highest variation in frequency 
(among CDR3s) originate. Among the top 20 such high variation 4-mers, we observed 
that while some mainly originate from V or J-gene regions, many originate from the N1, 
D, N2 regions including the k-mer with the highest variance (GGGG) which originates 
primarily from the N1, D, N2 regions (Fig. 2d, e), suggesting that k-mers with the most 
potential for discriminating between CDR3s arise from such high diversity regions. To 
confirm this further, we built a classification model using Random Forests with clusters 
(within sample clusters) or sub-repertoires (across sample cluster matches) as classes, 
and nucleotide 4-mers, one hot encoded V-genes, J-genes, VDJ, and VJ as variables, and 
evaluated the importance of the variables in classifying clonotypes into clusters or sub-
repertoires. This showed, although J-genes have a higher median importance, k-mers in 
general have the highest importance in defining the classes (in clusters within a sample, 
Fig.  2f ), with more k-mers having importance values above the highest valued J-gene 
than the number of all possible 13 J-genes (in the 8 sample sub-repertoires, Additional 
file 1: Fig. 2Se). Analysis of where k-mers within the top 20 most discriminative variables 
originate showed more than half arise primarily from N1,D,N2 regions both for clusters 
within sample (Fig.  2g) and even more so in the sub-repertoires across the 8 samples 
(Additional file  1: Fig.  2Sf ), giving similar results to what we observed with the most 
variable k-mers. Similar analyses with all k-mers that primarily (most frequently) origi-
nate from any of the N1, D and N2 regions showed that a subset of such k-mers had the 
Fig. 2 CDR3 sub-repertoire matching in samples of two unrelated individuals. a hierarchical clustering of 
CDR3 cluster centroids from samples CD005 (black) and CD006 (green) from our CD PBMC dataset identified 
32 sub-repertoires of which 30 (94%) had cluster representatives from both samples. Branch colors indicate 
sub-repertoires. Only 2 of the 32 (6%) sub-repertoires (shown in black dots) are homogenous, containing 
cluster centroids from only one sample. b V-, J-, VJ- and VDJ gene usage frequency was compared between 
clusters coming from the two samples, the percentage of sub-repertoires with significantly different gene 
usage with p value below 0.05 (using chi-square test of independence) is shown. c Number of different 
possible 4-mers that start at each position is estimated using Shannon’s entropy for 42nt long CDR3s, highest 
entropy is observed in positions in which CDR3s have the N1 and N2 region. Similar result was obtained in all 
samples. 4-mers that are not completely within the N1 or N2 region but either end or start in the regions are 
counted towards them. d Top 20 4-mers with the highest variance in frequency across the 5000 subsampled 
CDR3s within a single sample (CD005) is shown. e The frequency of where (in V, N1, D, N2, J) the top 20 most 
variable 4-mers are found in the CDR3s is shown. f The classification importance of k-mers and genes in 
distinguishing 4-mer based clusters within a single sample (CD005) is shown. g The frequency of where (in V, 
N1, D,N2, J) the top 20 most discriminative 4-mers (ordered left to right) are found in the CD005 repertoire is 
shown
(See figure on next page.)
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highest importance scores compared to all variables both for classifying within sample 
clusters or cross-sample sub-repertoires (Additional file  1: Fig.  2Sg and 2Sh). In sum-
mary, these results suggest that CDR3β clusters and sub-repertoires defined by k-mers 
capture discriminative information from the non-templated, junctional insertion/dele-
tion regions and do not simply recapitulate clonotype grouping by simple germline gene 
usage, as a result leading to better clustering of clonotypes with shared immunological 
information both within and across samples.
GGGC GCGG ACAG AGCG CCAG
GGAC GCCA GCAG CAGT CAGG
AGGG GAGC CCCC GGAG AGCT































































































































































































































































































































































































































































































































































































































































































































































































TAGC GACT AAAA GACA
ACTA GGAG GCAG ACAG CTAG
CGGG GCTT AGCG GCGG AGCT
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We then investigated the extent of sub-repertoire sharing when there are more 
number of samples in the analysis. We performed the clustering and cluster match-
ing analysis on all 8 samples of our celiac disease (CD) PBMC datasets, from both 
pre-gluten challenge (day 0) and post-gluten challenge (day 6) conditions, at different 
sequencing depths per sample (Fig. 3). The proportion of sub-repertoires containing 
representative centroids from only one sample was negligibly low in the ten analyses 
done at different repertoire depths (Fig. 3a), while at minimum 10–20% of sub-reper-
toires contained CDR3 cluster centroids from all 8 samples. But cumulatively, more 
than ~ 40% (with hc matching) and 60% (with km matching) of the sub-repertoires 
contain centroids from at least 6 of the 8 samples (Fig. 3b), suggesting that enough of 
the sub-repertoires are present in multiple samples to allow comparison of sub-reper-
toire abundance at the population level, and to enable indirect detection of condition 
relevant CDR3s.
Applying the method on our datasets, for the CD PBMC dataset (n = 4), the method 
identified 2315 and 2467 CDR3β sequences that showed significant enrichment fol-
lowing gluten exposure when using nucleotide 4-mer and amino-acid 3-mer feature 
vectors respectively. For the CD Gut dataset (n = 5), the method identified 2291 and 
2404 enriched CDR3βs during active celiac disease when using nucleotide 4-mer and 
amino-acid 3-mer feature vectors respectively. Figure  4 shows the top 20 enriched 
CDR3βs detected from both datasets when using nucleotide 4-mer and amino-acid 
3-mer feature vectors (for the list of all detected CDR3s see Additional file 2). Con-
sidering the high diversity of immune repertoire datasets, the results of the analyses 
performed with nt 4-mers and aa 3-mers showed high overlap (as high as 70% in CD 
PBMC and 78% in CD Gut, Additional file 1: Figure 3Sa and b), suggesting results of 
comparable relevance could be obtained by either feature vectors, although the latter 
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Method ● ●hc kma b
Fig. 3 Sub-repertoire detection across many samples. CDR3 clustering, and sub-repertoire detection using 
both hierarchical clustering (hc) and k-means (km) clustering of the CDR3 cluster centroids was performed 
for all 8 CD PBMC samples. a Shows proportions of sub-repertoires containing CDR3 cluster centroids from 
only n samples, dots are the estimate from each of 10 analyses from subsampled repertoires with sequencing 
depths of 1 to 10 thousand unique nucleotide CDR3s per sample. b The cumulative proportion of 
sub-repertoires containing representative clusters from n samples or more is shown; the cumulative at each n 
is computed as the mean proportion of n represented samples from the 10 resample analyses
Page 8 of 21Yohannes et al. BMC Bioinformatics          (2021) 22:159 
To assess the method’s sensitivity to detect CD associated clonotypes, and its abil-
ity to detect enrichment beyond clonotype size differences due to sampling variation, 
we applied the nucleotide 4-mer analysis on same condition CD PBMC samples pre-
pared by a pooling and random sampling strategy (see the Analysis of same condition 
















































































































































































































































Fig. 4 Differentially abundant CDR3β sequences identified by the method. The top 20 significantly 
differentially enriched CDR3β sequences during gluten exposure are shown for a CD PBMC and b CD Gut 
datasets when using nt 4-mer feature vectors. The result obtained using aa 3-mer feature vectors is on c for 
CD PBMC and d for CD Gut datasets. Abundance is shown in log10 scale, from low abundance (white) to 
higher abundance (red). GFD treated samples are shown in light blue and gluten exposed samples are shown 
in orange bars at the top
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samples  section in  Additional file  1). For both pre-gluten exposure day 0 and post-
gluten exposure day 6, ten unpaired comparisons of same condition, randomly drawn 
samples, identified negligibly low numbers of enriched clonotypes with a mean of 1.5 
among day 0, and 2.4 among day 6 same condition comparisons (Additional file  1: 
Fig. 5S), suggesting that the method is sensitive to sampling variation in picking rel-
evant clonotypes.
For method validation, we compared the detected CD associated enriched CDR3βs 
to known celiac disease associated CDR3β sequences in the literature. The detected 
enriched CDR3βs had significantly increased usage of previously reported TRBV-
genes associated with gluten-reactive CDR3β sequences [17, 18, 23–26], with the 
enriched CDR3βs from CD PBMC dataset showing biased usage of TRBV-gene families 
4,5,7, and 9, specifically TRBV04-02, TRBV07-02 and TRBV09-01 (Fig.  5a, and Addi-
tional file 1: Fig. 4Sa). The enriched CDR3βs from CD gut dataset also showed biased 
usage of previously reported TRBV06-01 in addition to new interesting genes such as 
TRBV10-03 (Fig. 5b, and Additional file 1: Fig. 4Sb). Furthermore, per-position amino 
acid usage analysis of the enriched CDR3s bearing some of the over-used TRBV genes 
provides interesting insights. Besides detecting CDR3βs with the already known amino 
acid motifs in gluten-reactive CDR3βs with a dominant usage of Arginine (R) in posi-
tion 6 [17, 18] (Fig. 5c and Additional file 1: Fig. 4Sc), the method identified other previ-
ously unreported over used genes such as TRBV03-01,TRBV15-01 and TRBV10-01 in 
the detected enriched CDR3s with previously under-appreciated per-position amino 
acid usage patterns, such as the previously reported (although in Humanized HLA-DQ8 
transgenic mice) over-usage of Glutamic acid (E) and Aspartic acid (D) at position 6 of 
gluten specific TCR CDR3βs [27] (Additional file 1: Fig. 4Sc and d). In addition, except 
in the nucleotide subsequence based analysis of CD Gut, the list of enriched CDR3βs 
from both CD PBMC and CD Gut contained significantly high number of previously 
reported CD-associated CDR3β sequences by Qiao et al., Han et al. and Petersen et al. 
[17, 25, 26] than was expected by chance, as determined by both using a randomiza-
tion test or a straight forward comparison to the proportion of previously known celiac 
disease associated CDR3s in the total repertoire of the combined dataset of all samples 
(Table 1 and Additional file 1: Table 4S, see Additional file 1: Tables 2S and 3S for the list 
of previously known celiac disease associated CDR3 identified by the method). There 
was also high overlap between the known CD clonotypes detected by the nt 4-mer and 
aa 3-mer approaches (Additional file 1: Fig. 3Sc and d). The method detected known CD 
associated CDR3s mostly from CD4 + T-cells in the CD PBMC (as determined by refer-
ring to the T-cell types in the previous reports bearing the CDR3s) and CD8+ T-cells 
from the CD gut datasets (Table 1). There was no detection of any known CD associated 
CDR3βs among the list of de-enriched sequences obtained from both nucleotide 4-mer 
and amino-acid 3-mer based analyses of CD PBMC, while for CD Gut, two known CD 
clonotypes were de-enriched in the nucleotide 4-mer and one in the amino-acid 3-mer 
analyses (Additional file 1: Table 3S).
We also used the method on the publicly available yellow fever vaccination T-cell 
CDR3β repertoire datasets, YFV PBMC (n = 9) [13] and YFV PBMC from twins (n = 6) 
[16] to identify CDR3β sequences responding to the YF-17D vaccine. We compared 
the total pre-vaccination (day 0) PBMC repertoires to the total post-vaccination (day 
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14 or day 15) PBMC repertoires. The list of enriched CDR3βs the method identified 
contained significantly high numbers of vaccine induced CDR3βs that were reported 
in the original publications (Table  1 and  Additional file  1: Table  4S. For the list of all 
detected YFV associated CDR3s see Additional file  2). For the YFV PBMC dataset, it 
identified 2620 enriched clonotypes across all individuals of which 697 (~ 27%) are in 
the YFV-induced day 14 effector CD8+ T-Cell CDR3βs that were statistically deter-
mined to be expanded (compared to day 0 total repertoires) in the original publication. 
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Fig. 5 Characteristics of the differentially abundant CDR3β sequences in CD PBMC and CD Gut. 
The differentially enriched CDR3β sequences had biased usage of TRBV genes that are known to be 
over-represented in gluten reactive CDR3β sequences in previous studies, such as TRBV07-02 and TRBV09-01 
from CD PBMC (a), and TRBV06-01 from CD Gut (b) (observed frequencies are shown in red, mean frequency 
from randomly generated sets of CDR3s are shown in blue). Significantly over-used amino acids at each 
position are shown for the enriched CDR3β sequences that use TRBV genes detected to be over-used from 
CD PBMC (c) and CD Gut (d), amino acids are colored according to their properties. The information content 
of significantly overused amino acids at each position is shown in bits on the y-axis. TRBV and per-position 
amino acid over-usage is assessed by comparing the observed frequencies in the set of differentially 
enriched CDR3s to that obtained by chance in 100 randomly sampled CDR3s of same size, TRBV gene and 
CDR3 length, with p < 0.05 considered significant (gene names indicate TRBVgene::CDR3 length::number of 
CDR3s in the enriched list with the Vgene and CDR3 length). The results from using nt 4-mer feature vectors 
are shown
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Similar analysis in the original DeWitt et al. study identified 848 such enriched clono-
types across all samples that were also present in the expanded YFV-induced day 14 
effector CD8+ T-Cell CDR3βs, showing that we obtained comparable results by com-
paring the sample groups directly. Since we compared the total day 14 versus day 0 rep-
ertoires, the identified enriched clonotypes contain not just CD8+ but also expanded 
T-cells that are CD4 + and other CD8+ T-cells that do not have the exact markers used 
to sort for the YFV-induced day 14 effector CD8+ T-Cell population, as was noted simi-
larly in the original publication [13]. For the twin YFV PBMC dataset, the method iden-
tified 4152 enriched clonotypes of which 2058 (~ 50%) were present in the expanded 
clonotypes reported by Pogorelyy et al. [16]. Interestingly, 223 of the detected enriched 
clonotypes for the twin YFV PBMC dataset were present in the expanded YFV-induced 
day 14 effector CD8+ T-Cell CDR3βs of the YFV PBMC dataset from DeWitt et al., of 
these, 122 were detected only by our method and were not present in the expanded clo-
notypes reported by the twin YFV PBMC study by Pogorelyy et al. [16]. Furthermore, 
we checked the number of YFV (A02-NS4b214−222–specific) versus CMV (cytomegalovi-
rus) specific TCRβ sequences in our list of enriched clonotypes as was done in the origi-
nal study by Pogorelyy et  al. Our method identified no CMV-specific clonotypes, and 
identified significantly more published YFV-specific clonotypes with exact matches than 
was reported among the expanded clonotypes in the original study (Additional file  1: 
Table 5S). Overall, the results from the YFV datasets suggest that the method can find 
utility in various study types where detection of T-cell clonotypes with significant expan-
sion is required.
To benchmark method performance, we compared the method against four recently 
published methods, as well as against results obtained by the method when using ger-
mline gene usage for grouping clonotypes instead of k-mer based clustering (in step 1 
and 2 of the method). Using our CD PBMC dataset, we looked at how many of the 56 
previously known CD-associated CDR3s (that exist in the CD PBMC dataset) the meth-
ods detect, as well as evaluated the methods’ recall and precision. Our method (RepAn, 
nt 4-mer based) identified 14 of the 56 known CD associated CDR3s as differentially 
enriched, whose proportion in comparison to total identified enriched clonotypes is 
similar to all other methods except ALICE and the public only methods, which are all 
highly conservative and thus have much lower recall (Additional file 1: Table 6S). The 
Table 1 Previously known condition-associated CDR3s in the list of DA enriched CDR3s identified 
by the method (using randomization test)
* Previously reported CD associated CDR3s are assumed likely CD4 and CD8 based on their reported CD4 and CD8 status in 
the papers they were reported. For some such information was not available
p values show non‑significant results
Dataset known condition-
associated CDR3s in all 
samples (*likely CD4, CD8)
Feature space Known condition-
associated CDR3s in DA 
enriched (likely CD4, CD8)
Permutation test p 
value (CD4, CD8)
CD PBMC 56 (20, 36) nt 4-mer 14 (9, 3) p = 0.0 (0.0, 0.09)
CD PBMC 56 (20, 36) aa 3-mer 10 (7, 2) p = 0.0 (0.0, 0.33)
CD GUT 50 (23, 24) nt 4-mer 3 (0, 3) p = 0.48 (1, 0.05)
CD GUT 50 (23, 24) aa 3-mer 5 (1, 4) p = 0.13 (0.85, 0.02)
YFV PBMC 12,092 nt 4-mer 697 p = 0.0
Twin YFV PBMC 5730 nt 4-mer 2058 p = 0.0
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method has the second highest recall and precision, next to the DeWitt’s method or 
third highest in precision if we include the Yohannes et.al method that detects only pub-
lic clonotypes. It outperformed all germline gene usage based variants of RepAn in both 
recall and precision. Thus, the method provides detection of both public and private 
clonotypes with comparatively high recall and precision, while being the only method 
that allows direct population level analysis (Additional file  1: Table  6S, see Additional 
file  2  for the list of the 56 CD-associated CDR3s in the CDPBMC dataset along with 
those detected by the methods). We note that the shared detection between any two of 
these methods is rather low (Additional file 1: Fig. 6S) and thus a criteria of detection in 
at least one other method for assessing precision and recall was used.
Discussion
The computational pipeline we present in this work allows comparison of total immune 
repertoires between sample groups to identify both public and private CDR3 clono-
types associated with conditions. To our knowledge, this is the only currently available 
method for direct population level comparison of TCR CDR3 repertoires, with incor-
porated population-wide statistical assessment of TCR clonotypes’ condition-relevance, 
and thus provides improved ability for examining and monitoring immune responses.
We made two main assumptions in our proposed method. Firstly, we assumed that the 
immune repertoire specific to an antigen or epitope would contain T-cell clones with 
high similarity in their T-cell receptors (TCRs) forming a cluster (or group of clusters) 
that is distinct from other T-cells not specific to the antigen. This assumption originally 
stemmed from observations of the celiac disease associated CDR3β sequences in our 
and other previous studies [9, 17, 28]. Recent works by Dash et.al. and Glanville et.al. 
[21, 22] showed that tetramer sorted antigen specific TCRs from different individuals 
have high sequence similarity and could be grouped into clusters with common specific-
ity to an antigen, further justifying the validity of our assumption. Secondly, we assumed 
that the clusters of TCRs specific to an antigen encode an important immuno-genomic 
information in the immune response that is shared across unrelated individuals and 
could probably be detected from the global repertoire and across treatment conditions. 
We show that k-mer frequency vectors capture immune information from all parts of 
CDR3 sequences beyond what could be captured by simple grouping of CDR3s based 
on germline gene usage, with the most discriminative k-mers between sub-repertoires 
dominated predominantly by those arising also from non-templated insertion/deletion 
regions of CDR3s. Our method based on such nucleotide 4-mers or amino acid 3-mers 
allowed dissection of total immune repertoires into units (meaningful sub-repertoires) 
that exist across individuals, and thus successfully identified previously reported and 
new condition-associated CDR3β sequences (both private and public) from the datasets 
we analyzed with better precision, demonstrating the validity of our assumption.
Various ways of representing the CDR3 sequences have been used in recent immune 
repertoire studies in order to ascertain sequence similarity. Thomas et al. used Atchley 
factors to represent amino-acid subsequences of CDR3 [29, 30], although applied for 
classification of total repertoire samples. Direct comparison of the receptor sequences 
is also possible without CDR3 representation by numeric vectors. Dash et  al. defined 
a metric called TCRdist, that uses the amino acid receptor sequences directly, with a 
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weighted Hamming distance of the amino acid sequences of not only the CDR3, but also 
the CDR1 and CDR2 of both alpha and beta chains to determine the distance between 
two T-cell receptors [21], while Glanville et  al. combined hamming distance between 
amino acid CDR3 sequences, with usage patterns of k-mer subsequences in structurally 
determined positions of high antigen contact propensity to measure distances between 
pairs of CDR3s [22]. We represented CDR3 sequences using a simple, high dimensional 
subsequence frequency vector, which was then used to define distance in that feature 
space and cluster CDR3 sequences into similar groups. Greiff et al. recently found such 
immuno-genomic representation of CDR3s to be highly meaningful in allowing the pre-
diction of private versus public CDR3 sequences with high accuracy [31]. We showed 
that such k-mer frequency based representation allows detection of both public and pri-
vate condition relevant clonotypes. Particularly for the private clonotypes, their impor-
tance is assessed by proxy, i.e., via the detection of their sequence composition similarity, 
and importantly their repeated detection as relevant clonotypes within sub-repertoires 
deemed differentially abundant in multiple downsampled analyses, providing replicated 
evidence of relevance.
We evaluated method performance by comparing the detected CDR3s to known anti-
gen binding condition-associated CDR3s from previous studies. The method detected 
statistically significant numbers of known condition-associated CDR3s (for both celiac 
disease and yellow fever vaccination datasets) than could be obtained by chance. The 
detected CDR3s showed significant bias in V-gene and per-position amino acid usages 
typical of known condition-associated CDR3s, validating the high usability of the pro-
posed method. The method also compared favorably to recently published methods in 
detecting known celiac disease associated clonotypes enriched in our dataset. It showed 
relatively high recall and precision in an assessment using concordant detection of 
enriched clonotypes between the methods to define possible true and false detection.
While we did not directly assess the impact of HLA-type differences in the method’s 
performance, we presume that the method could pick HLA-associated TCRs unless 
HLA-types are fairly randomized in the compared groups. Our CD datasets were 
matched for at least one copy of HLA-DQ2, which has the strongest genetic association 
to CD. No HLA information was available for the public dataset YFV PBMC, while the 
twin YFV PBMC dataset was HLA-matched for HLA-A*02, which restricts an immuno-
dominant YFV epitope  (NS4b214−222), but is not otherwise the only HLA association to 
YFV [32, 33], thus the results from the YFV datasets were largely HLA-independent. The 
method can be extended to include k-mer frequencies in the other complementarity-
determining regions of the TCR beta-chain (CDR1 and CDR2), and alpha-chain (CDR1, 
CDR2 and CDR3), capturing a more thorough information of clonotypes’ specificity to 
antigens. In the case of CDR1 and CDR2 (encoded by the V genes), this could allow the 
method to be more sensitive to the effects of HLA, as CDR1 and CDR2, unlike CDR3, 
make contact only with the Major histocompatibility complex (MHC), and not directly 
to the antigen peptide in the pMHC site, modulating TCR specificity indirectly [34].
Condition-associated TCR CDR3s are not fully known for many multifactorial auto-
immune or cancer related diseases. For diseases with known antigen, such as celiac 
disease (CD) where some information about the antigen (gluten) is known, specific 
protocols like tetramers and/or sorting would have to be designed to characterize 
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the antigen-specific T-cells, their CDR3s, and other phenotypes in detail. Although 
highly useful, such methods designed to select antigen-specific repertoires are unable 
to detect T-cell clones responding to other important immune targets other than glu-
ten, either self or foreign, possibly ignoring a crucial part of the immune response 
that would explain the pathology all the more. Methods such as the one presented in 
this study that attempt to detect condition-relevant T-cell clones from total reper-
toires, without necessarily having prior knowledge of the immune target (or targets), 
coupled with techniques that profile the overall gene expression of the condition-
associated T-cell clones, would potentially provide a highly comprehensive picture of 
the adaptive immune response. This leads to a much more complete understanding of 
such diseases in-terms of unraveling the hidden pieces of the puzzle, and could pro-
vide ways for the prediction of the unknown immune targets. For diseases in which 
the antigens are totally unknown, the application of such methods could lead to the 
identification of the associated CDR3 sequences that could serve as immune-response 
bio-markers with possible clinical application, as well as enabling their comparison 
to other known disease associated CDR3 sequences available in CDR3 databases [35, 
36], potentially allowing prediction of their possible target antigen via specificity esti-
mates that can be obtained using recently reported TCR-epitope specificity predic-
tion methods [37].
Main limitations of the methodology include restricted repertoire representa-
tiveness and computational intensiveness, both arising from the immense diversity 
of immune repertoires. There are millions of unique CDR3 sequences in every per-
son, each representing a T-cell clone, and most found only in a single person. Only 
tens to hundreds of thousands of unique CDR3s are being sampled with the current 
Repseq technology per sample. Since calculating pairwise distances for potentially 
hundreds of thousands of CDR3s is computationally intensive, if not infeasible, we 
adopted repeat resampling and applied the methodology a repeated number times 
with randomly selected smaller repertoire samples. The number of repeat resample 
runs chosen and the repertoire size of each repertoire resamples determines the com-
putational resources required and exhaustiveness of the result. Additionally, usage 
of bigger k sizes for the k-mer frequency based CDR3 encoding is computationally 
intensive. While our choice of k = 4 for nt and k = 3 for aa is based on their successful 
applications in other studies (see Methods), analyses of ks from 2 to 8 for nt k-mers 
showed no substantial difference, or gain in detection capacity, while at the same time 
resulting in significant increase of computational requirements as k increases (Addi-
tional file 1: Fig. 7S). As Repseq datasets are already huge with thousands of clono-
types in multiple samples, the use of smaller k is a better tradeoff. We ran the method 
for all datasets on a supercomputer cluster using a single node with 24 cores. Running 
the method with 100 resample rounds for the CD PBMC and CD Gut datasets took 
around one hour using nt 4-mers, and 15 and 8 h respectively, when using aa 3-mers. 
A combined memory of approximately 100  GB was used for both nt and aa based 
analyses. For the two bigger YFV datasets, 600 resample rounds needed 40 to 50 h for 
an nt 4-mer based analysis with a maximum of 322 GB of memory used (Additional 
file 1: Table 7S). As the results from using nt 4-mers are highly comparable to those 
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obtained by aa 3-mers, using the method with the nt 4-mer option is the better option 
for bigger datasets whenever clonotype nucleotide data is available.
Conclusions
To conclude, by clustering CDR3 sequences into groups with similar immuno-genomic 
features, and finding their close matches across different samples, we showed that con-
dition-associated CDR3 sequences that are private or public, and with significant dif-
ferential abundance, can be detected by direct comparison of groups of samples. The 
approach paves the way for the identification of private or public CDR3s (and their fea-
tures) associated with diseases or other important phenotypes such as HLA-type, fur-
ther allowing comprehensive categorization and archiving of T-cell clonotypes. This has 
a vast potential in understanding the adaptive immune response in various disease con-
ditions and disease development stages, identifying unknown self or foreign antigens in 
diseases with unknown immune targets, examining immunological history encoded in 
the immune repertoire, and possible early prediction of the adaptive immune response.
Methods
Our methodology narrows down the highly diverse immune repertoire data and helps to 
identify disease associated differentially abundant CDR3 sequences by comparing sam-
ples from two treatment groups. As input, it expects high-throughput genomic T-cell 
receptor CDR3 sequences (of either CDR3α or CDR3β) in immunoseq format [38] for 
every sample, which is a tab-delimited text file with each row containing information 
about a CDR3 and its features (its Nucleotide & Amino acid sequences, CDR3 length, 
frequency, V-,D-,and J-gene segment usage, etc.). Additionally, it also requires infor-
mation regarding the experimental condition of every sample. The method can also 
accept MiXCR [39] formatted cDNA repertoire data, in which case the analysis results 
should be interpreted as differential expression of clonotypes instead of clonal expan-
sion (enrichment) or contraction (de-enrichment). Referring to each such repertoire file 
simply as a sample, the method processes the samples in four major steps to identify dif-
ferentially abundant CDR3 sequences (Fig. 1):
1. CDR3 clustering: each CDR3 in a sample is first represented using a high dimen-
sional k-mer frequency vector by counting the frequency of each possible contiguous 
nucleotide (nt) or amino acid (aa) subsequences in the CDR3. We have typically used 
k = 4 for nt k-mers, resulting in a feature vector size of 256, or k = 3 for aa k-mers 
resulting in a feature vector size of 8000. Our choices for these ks are based on previ-
ous successful applications of using sequence composition for meaningful unsuper-
vised clustering in similarly high diversity datasets. Nucleotide 4-mer (tetranucleo-
tide) frequencies have been used extensively in metagenomic binning for assignment 
of reads into taxonomic groups [40–42], and we surmised, its adoption in nucleotide 
composition based TCR grouping is reasonable as TCR repertoires may mirror the 
major groups of environmental antigens the TCRs engage. For amino acid TCRs, 
clustering a 3-mers based amino acid Atchley factor encoding of TCRs has been 
shown to allow better classification of a whole repertoire’s immunization status [29].
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 Next, the high-dimensional k-mer frequency vectors are used to perform unsuper-
vised clustering of the CDR3 sequences within each sample (using agglomerative 
hierarchical clustering, with the complete linkage method which showed better 
cluster stability with more number of clusters-or “zooming-in”, Additional file 1: Fig-
ure 1S). We employed the Euclidean distance to determine the distance between a 
pair of CDR3 k-mer frequency vectors. After the hierarchical clustering, the dynamic 
tree cut algorithm is used to define the CDR3 clusters in each sample [43].
2. Cluster matching across samples: For each cluster in each sample, the average fre-
quency for each k-mer is computed from the members of the cluster to get the clus-
ter centroid. Here, k-mer frequencies in member clonotypes are not weighted by 
CDR3 abundances in the underlying data in order to have centroid k-mer frequen-
cies reflect only the basic subsequence compositional characteristics of clusters, 
and to avoid bias due to sequencing depth differences when matching across sam-
ples. The centroids of clusters from all samples are collected together, and unsuper-
vised clustering of the centroids is performed using either hierarchical clustering or 
K-means to group centroids based on closeness in k-mer frequency profiles. When 
using k-means, clustering of the centroids is performed using a k that has the maxi-
mum optimal-k (oK) score:
where nS is the proportion of clusters with silhouette value greater than the average 
silhouette (over all clusters), and avS is the average silhouette shifted to be between 0 
and 1, by adding 1 and dividing by 2. oK values range from 0 to 1. To determine the k 
with maximum oK score, oK is computed for all k starting from the minimum to the 
maximum number of CDR3 clusters per sample observed across all samples (from 
the result of step 1).
 Next, each cluster of centroids is examined and, if multiple centroids from one sam-
ple are determined to be in the same centroid cluster, the clusters of such centroids 
are merged in the original sample and the centroid updated. Otherwise, all clusters of 
centroids representing matching clusters from multiple samples (not necessarily all 
samples) are retained.
 Given N samples, this step generates a cluster match table with oK rows and N col-
umns, in which row entries represent CDR3 cluster labels from all samples that are 
close (or have matching) centroids, representing underlying features encoding con-
served immunological features in all N or some of the samples (matching clusters 
may not be found in all samples). We refer to each row in this cluster match table as a 
sub-repertoire.
3. Differential abundance testing: sub-repertoires that exist in at least x number of sam-
ples per group are first selected (default is in at least 3). A sub-repertoire abundance 
matrix is then generated for the selected sub-repertoires, which contains the abun-
dance of each sub-repertoire in each sample. This sub-repertoire abundance matrix 
can be generated in different ways. Typically, the original samples are first normal-
ized to same total CDR3 sizes (abundances). Then, the abundance of a sub-repertoire 
in a sample is calculated as the sum of CDR3 counts belonging to that sub-repertoire 
in the sample; or the relative frequency of that sum is used as a relative abundance 
oK = (nS+ avS)/2,
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estimate; or to avoid bias in the previous two abundance estimates that might arise 
due to differences in the number of CDR3s per sub-repertoire in a sample, the rela-
tive clone size in sub-repertoires is used as a proxy for abundance (i.e., average clone 
size in sub-repertoire / average clone size in sample). Next, for each sub-repertoire, 
differential abundance testing between the two groups of samples is performed using 
various tests. We used t-test, and two-class, unpaired, RankProd [44] test, both of 
which work well. The CDR3 sequences belonging to significantly differentially abun-
dant (DA) sub-repertoires are then extracted from each sample; these are candidate 
DA CDR3 sequences.
4. Filtering candidate DA CDR3s: DA sub-repertoires are not “pure” and contain 
CDR3s that are not necessarily associated with the condition thus requiring further 
filtering. To do this, all candidate DA CDR3 sequences (i.e., all CDR3 sequences that 
are in DA sub-repertoires) are first ranked as follows. For each candidate CDR3 i, a 
rank sum,  Ci, is computed by adding the candidate’s ranks from 6 factors:
where  R1i is candidate i’s importance in classifying the groups (random forest mean 
decrease in accuracy [45, 46]),  R2i is its mean fisher’s exact test p value calculated by 
comparing its abundance in each paired samples separately if data is paired/matched, 
or mean of mean fisher’s exact test p values calculated by comparing its abundance 
in a sample to every sample in the other group if data is unpaired/unmatched,  R3i 
is its mean odds ratio from the fisher’s exact test calculated for  R2 with paired and 
unpaired samples handled as in  R2,  R4i is its mean estimated increase in nucleotide 
to amino acid (nt-to-aa) ratio in the condition group compared to the control group 
(nt-to-aa in condition / nt-to-aa in control) to account for its level of convergent 
selection, calculated as a mean of such values obtained for it from each paired sam-
ples separately if data is paired/matched, or as mean of mean such values obtained 
for it by comparing its nt-to-aa in each sample to every sample in the other group 
if data is unpaired/unmatched,  R5i is the difference in the number of samples per 
group in which it exists, to account for its degree of condition induced “public-ness”, 
and  R6i is the number of times it has been detected in repeat resample runs of the 
DA analysis (Repseq datasets are huge datasets and require a lot of computational 
resources, we thus perform repeat sub-sampling of the raw datasets and run the dif-
ferential abundance analysis of steps 1–3 for each resampled datasets, the candidate 
DA CDR3 sequences from each round are collected, CDR3 sequences that have been 
detected as candidate in multiple repeat resamples are given higher rank, i.e., rank 
of 1). The ranking in each factor is defined differently for assessing enrichment and 
de-enrichment. When assessing enrichment highest rank is given for highest mean 
decrease in accuracy for  R1, smallest p value for  R2, highest odds ratio for  R3, highest 
nt-to-aa ratio for  R4, highest increase in detection in the condition/treatment group 
for  R5, and highest number of detection in multiple runs of the analysis for  R6. For 
assessment of de-enrichment, highest rank is given for highest mean decrease in 
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for  R4, highest decrease in detection in the condition/treatment group for  R5, and 
highest number of detection in multiple runs of the analysis for  R6. The minimum 
value of 1 in each factor R signifies high rank. Since the range of rank values is dif-
ferent for each rank type, all Rs are scaled to be between 0 and 1 by subtracting the 
minimum and dividing by the range. We then calculate the p value for  Ci using a 
randomization test, as the proportion of n rank sum values, calculated from n per-
mutations (random shuffling of all Rs from the 6 factors, we typically used n = 1000), 
that are equal or less than  Ci. We consider candidate DA CDR3s with C p values less 
than 0.05 and q-value (minimal FDR at each p value) less than 0.05 as differentially 
abundant CDR3s. All six ranking factors were given equal weight in our analysis in 
the calculation of the rank sum C, but different weights could be used for each factor 
depending on the application. For false discovery rate estimation, we used a decoy-
based strategy by including in the analysis randomly drawn CDR3 sequences from a 
reference database of healthy TCR CDR3 PBMC repertoires to each sample’s reper-
toire data. The rate of false detection of the decoy CDR3s was used to estimate the 
FDR and q-value at each p value level for all candidate CDR3s ordered from smallest 
to highest C p values.
Datasets for testing the method
We used four TCR CDR3β immune repertoire datasets to test the method (Additional 
file 1: Table 1S). Celiac disease (CD) PBMC (n = 4) and Gut (n = 5) datasets of our celiac 
disease study cohort [9], yellow fever vaccination (YFV) PBMC dataset from DeWitt 
et  al. (n = 9) [13] obtained from the public immune repertoire database, immuneAC-
CESS, of Adaptive Biotechnologies (immuneACCESS, Adaptive Biotechnologies, Seat-
tle, WA. Available from: http:// adapt ivebi otech. com/ pub/ dewitt- 2015- jvi), and twin 
yellow fever vaccination (twinYFV) PBMC dataset (n = 6) from Pogorelyy et  al. [16] 
obtained from their github (https:// github. com/ mptou zel/ pogor elyy_ et_ al_ 2018).
Method application on test datasets
We applied the method in the following manner for the celiac disease TCR CDR3β 
repertoire datasets in this work: We filtered out clonotypes with a size of 1, then, (1) 
100 runs of steps 1 to 3 of the pipeline using randomly selected subsamples of 5000 
unique CDR3β sequences for each sample. (2) Within sample CDR3β clustering using 
either nucleotide 4-mers or amino acid 3-mer feature vectors, and across sample 
cluster matching using k-means in step 2. (3) Sub-repertoire abundance matrix was 
generated by summing the abundance of CDR3s belonging to each sub-repertoire in 
each sample. Sub-repertoire level differential abundance detection was performed on 
sub-repertoires that exist in at least 3 samples per group using paired t-test with the p 
value cut-off of 0.1. We found from evaluations of results from multiple runs that the 
less stringent p value cut-off for comparing sub-repertoire abundances across sam-
ples helps increase the signal to noise ratio by providing the right level of “zooming-
in”, without compromising detection capacity in downstream steps of the pipeline. 
4) Combining the candidate CDR3βs from the 100 runs and performing the filter-
ing step, CDR3βs with p value and q-value less than 0.05 were then considered con-
dition-associated CDR3β sequences. The method was applied similarly for the huge 
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yellow fever vaccination datasets (YFV and twinYFV) with the following changes: a) 
performed 600 runs of steps 1 to 3 (instead of 100, to allow exhaustive assessment of 
all clonotypes in all samples) with subsamples of 5000 CDR3β sequences per sample 
in each run, b) and performed only nucleotide 4-mer based analyses. The selected 
numbers for repeated runs of steps 1 to 3 of the method with down-sampled data 
allow exhaustive assessment of nearly all clonotypes in each dataset (Additional file 1: 
Fig. 8S).
Detailed description of the datasets, benchmarking, and characterization of 
detected condition associated CDR3s is given in the supplementary information sec-
tion in Additional file 1.
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